Upcoming event
38th Annual EAU Congress
Back

Tags

Article of the Month, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROwebinar, Webinar
Show all

Application of the KEYNOTE-564 trial results to real life population: Which patients with advanced kidney cancer should receive adjuvant pembrolizumab

View

Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis

View

Decision-making and management strategies for patients with bilateral synchronous non-metastatic renal masses: Insights from a multi-centre European dataset

View

The detrimental effect of frailty status on renal function recovery after partial nephrectomy – long-term results from a prospective surgical cohort

View

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

The Lancet Oncology, May 2022

View

LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data

View

Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study

View

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564

View

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

View

What happens to the preserved renal parenchyma after clamped partial nephrectomy?

European Urology, May 2022

View

Prospective evaluation of circulating tumor DNA (ctDNA) in detecting early progression on immune checkpoint inhibitors in patients with advanced genitourinary cancers

View

Machine learning approach to predict pT3a upstaging of clinically localized renal cell carcinoma and oncological outcomes after surgery (UroCCR 15 study)

View
PreviousNext